Background : prior to the availability of recombinant human erythropoietin (r-EPO, epoetin), patients on dialysis frequently demanded blood transfusions and excessive iron therapy, exposing them to the risks of iron overload, transmission of viral hepatitis, and sensitization, which reduced the chances of successful transplantation . Recombinant human erythropoietin has been used for more than 20 years for the treatment of renal anemia, Epoetin-Alfa and -beta representing the common traditional preparations. By the modification of the molecule's carbohydrate moiety or structure a longer duration of erythropoietin receptor stimulation was achieved. The continuous erythropoietin receptor activator C.E.R.A. once or twice a month was found sufficient to achieve serum hemoglobin target levels. This study was aimed to identify the efficacy of C.E.R.A (Methoxy polyethylene glycol-epoetin beta in achieving and maintenance of hemoglobin level in patients with chronic kidney disease and patients on regular Hemodialysis therapy. Patients and methods: 145 patients with either CKD stage 4 & 5 (e GFR < 45 ml/min) on follow up in nephrology outpatient department or on regular Hemodialysis in nephrology unit Dubai hospital. In this center, the CERA approved by the local pharmacy authority was used for treatment of anemia in chronic kidney disease monthly dose of (100 mg for 70 kg patient) and adjusted according to monthly HB level during the trial period for reaching and maintaining target HB level of 11-12.5 g/dl. Results : Patients on HD 78 patients (53.8%) and CKD patients 67 patients the mean HB level at the end of study period showed statistically significant rise in whole patient cohort with HB START (8.882 ±1.272 g/dl) and at the end of 24month (11.119±1017 g/dl) With P-value (< 0.001). HB at start was (9.013±1.298 g/dl) and (8.769±1.246) g/dl for CKD and HD respectively slightly higher in CKD group however without statistical difference (P-value 0.250). HB level at the 24 month period (end of trial period) was found statically higher in HD group (11.305±1.197g/dl) than CKD group (10.903±1.116g/dl) again without statistical significance P-value (0.038). Conclusion: It could be concluded that the long acting erythropoietin stimulating therapy using continuous erythrpoeitin receptor activator ( CERA ) as once monthly dose is effective and safe in maintaining target HB level in both CKD patients and patients on maintenance hemodialysis and there was no recorded side effects of its use either by intravenous or subcutaneous use.
INTRODUCTION
The definition of anemia is controversial. The WHO defines anemia as hemoglobin (HB) <13 g/dL for men and <12 g/dL for women. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative, defines anemia in adult men and postmenopausal women as HB<12 g/dL, or <11 g/dL in a premenopausal woman the recently launched.
(1,2) HB levels starts to fall early in course of chronic kidney disease (CKD), at an estimated glomerular filtration rate (e-GFR) of less than 75 ml/min per 1.73 m2 in men and 45 ml/min per 1.73 m2 in women.
(3). Among patients under regular care and known to have CKD, the prevalence of anemia was found to be much greater, with mean HB levels of 12.8 ± 1.5 g/dl (CKD stages 1 and 2), 12.4 ± 1.6 g/dl (CKD 515 stage 3), 12.0 ± 1.6 g/dl (CKD stage4), and 10.9 ± 1.6 g/dl (CKD stage 5).
(4)
Prior to the availability of recombinant human erythropoietin (r-EPO, epoetin), patients on dialysis frequently demanded blood transfusions and excessive iron therapy , exposing them to the risks of iron overload, transmission of viral hepatitis, and sensitization, which reduced the chances of successful transplantation.
(5)
It is of outmost importance to identify anemia in CKD patients as it may signify nutritional deficits, systemic illness, or other conditions that warrant attention, and even at modest degrees, anemia reflects an independent risk factor for hospitalization, cardiovascular disease, and mortality.
(6)
Renal anemia is a multifactor process and its treatment has to focus on stepwise approach targeting all factors involved in this process notably iron deficiency should be treated before adding more expensive therapies such as (r-EPO) therapy. Erythropoietin is a complex physiologic process through which delivering sufficient oxygen levels in the body is maintained. It is primarily regulated by EPO, a 30-kD, 165-amino acid hematopoietic growth factor that is produced primarily by renal tubular and interstitial cells. Under normal conditions, endogenous EPO levels change according to O2 tension.
(8)
Recombinant human erythropoietin has been used for more than 20 years for the treatment of renal anemia, revolutionizing its treatment in patients with CKD when it was approved for use in the United States in 1989 .
(9)
Epoetin-Alfa and -beta representing the common traditional preparations. By the modification of the molecule's carbohydrate moiety or structure a longer duration of erythropoietin receptor stimulation was achieved. The continuous erythropoietin receptor activator C.E.R.A. once or twice a month was found sufficient to achieve serum hemoglobin target levels. Our study aim at identifying the efficacy of continuous erythropoietin receptor activator C.E.R.A ( Methoxy polyethylene glycol-epoetin beta (MPG-EPO; Mircera®, Roche, Basel, Switzerland) in achieving and maintainenance of hemoglobin level in patients with chronic kidney disease and patients on regular Hemodialysis therapy .
PATIENT AND METHODS
Observational open labeled follow up trial including 145 patients with either CKD stage 4 & 5 (e GFR < 45 ml/min) on follow up in Nephrology Outpatient Department (67 patients) or on regular Hemodialysis in nephrology unit Dubai hospital (78 patients), after patient informed consent and approval from ethical committee, Patient records confidentiality was assured follow up period of 24 months with primary end point achievement of the target hemoglobin level (11-12.5 g/dl ) at end of the study period .Patients who refused to sign the consent or who fail to comply with administration instructions were excluded from trial . The CERA approved by the local pharmacy authority was used for treatment of anemia in chronic kidney disease(CKD) a monthly dose of 1.2 mg/kg body weight (100 mg for 70 kg patient ) and adjusted according to monthly Hb level during the trial period for reaching and maintaining target HB level of 11-12.5 g/dl , dose reduction if target HB reached was done by reducing the frequency of administration to a maintenance once every 6 -8 weeks and increasing dose to achieve the target HB for those who fail to achieve adequate response was made by increasing dose to 150 mg up to 200 mg each month which was the highest dose administered throughout the trial period . Dose was given intravenous in HD patient group through the dialysis venous line at end of dialysis, and Subcutaneously in CKD patient group , compliance was followed up through administration injection cards given to patients enrolled and signed by the administering nurse at the injection clinic . Data regarding age sex and stage of CDK collected , HB level measured monthly during the study period and for ease of statistical analysis measures every 3 rd month was taken as referral points start , 3 month , 6 month , 12 month , 15 months , 18 months 21 months and 24 months ( end of study period ) Data was then tabulated, computerized and statistical analysis done using SPSS 16 software.
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RESULTS
Current data showed as illustrated in table (1) and figure (1) that age among the group was 65.8±13.66 years and the gender distribution was 84 female patients (57.9%) and 61 male ( 42.2%) the patients on HD 78 patients (53.8%) and CKD patients 67 patients (46.2%) . As shown in table (2) and figure (2) the mean HB level at the end of study period showed statistically significant rise in whole patient cohort with HB at START (8.882 ±1.272g/dl) and at 24month( 11.119±1017g/dl ) With Pvalue (< 0.001) . Table ( 3) showed the analysis of the patients subgroups, we found that there was insignificant difference between groups at the start and end of the study confirming the homogeneity of action and the significant changes found by the use of CERA in the patients at both groups as mentioned above. HB at start was (9.013±1.298g/dl) and (8.769±1.246)g/dl for CKD and HD respectively insignifant higher in CKD group than HD group P-value (0.250). On the other hand HB level at the 24 month period (end of trial period) was found higher in HD group (11.305±1.197g/dl) than CKD group (10.903±1.116g/dl) again without statistical significance p-value(0.038) still insignificant . TABLE (4) analysis of the changes in HB level through the study period, showed an initial significant rise in HB level 3 months in the whole patient groups (8.882±1.272g /dl) at start and (10.443±1.250 g/dl ) after 3 months. Another significant rise at interval 12 and 18 months of the trial with HB level (10.430±1.014 g /dl ) at 12 months and (11.312±1.534g/dl ) at 18 month P-value (<0.001) . No intergroup differences in CKD and HD groups was maintained throughout the study period as shown in table (5) . figure (3) showed the distribution of results of HG at start and 24 months of the study with clear demonstration of not only the significant rise in HB values but also the achievement of target hemoglobin in most of the patients in study group mostly all cross the reference line at 10g /dl . patient compliance to CERA was satisfactory especially with monthly single dose for patients in CKD group with good compliance and, no recorded side effects through the study period including less recorded pain at the injection side, we also did not report any case of of thrombocytopenia, gastrointestinal bleeds, or pure red cell aplasia identified in our center during the 24 month folw up period of the trial.
DISCUSSION
The result of our study showed a significant rise in HB level in all patients cohort and the efficacy of the CERA (continuous erythropoietin stimulating agents) in maintaining HB level within target range both in the CKD and HD groups. Our results come in accordance with results achieved by Ohashi et al, who proved that Once-monthly CERA therapy maintains stable Hb values with low intra-individual variability and few dose adaptations in CKD patients when administered entirely according to local practice, and the regimen is well tolerated . Macdougall et al, studied the pharmacokinetics and drug metabolism of CERA in CKD patiens and showed the efficacy and safety of once monthly admisinsteration in maintating serum level of the drug and continuous receptor activation .
(12)
We found no difference between efficacy of CERA compound in both the HD and the CKD groups and regarding the dose of admisstration either IV or SC this comes in accordance with the results achieved by Leypoldt et al , who confirms that intravenous administration of CERA drug is as effective as subcutaneous route in Hemodialysis And Hemodiafilteration Patients .
(13)
Luc Frimat et al , conducted a multicenter longitudinal observational trial on patients with chronic kidney disease and found proven efficacy of once monthly administration of CERA in those patients without recorded side effects this goes with the obseravation of our study .
(14)
A recent trial by Abeer et al , in Baghdad university , Iraq studied the efficacy and safety of CERA ( EPOEITIN BETA ) versus epoeitin alfa in 46 hemodialysis patients and concluded that methoxy polyethylene glycol-epoetin beta every two week effectively corrected chronic kidney disease (CKD) related anemia and was well tolerated and it is efficacy and safety is comparable to twice weekly epoetin alfa for anemia correcting in hemodialysis patients. This less frequent dosing schedule of methoxy polyethylene glycol-epoetin beta may offer clinicians and patients a simplified anemia management as compared to traditional erythropoietin (epoetin Alfa).
(15)
Although once monthly admisistration of CERA is the widely encountered practice, some trials have tested the efficacy and safety of using a lower initial dose of 0.6 mg/kg every two month with acceptable safety and efficacy profiles. 
17)
Arecent trial by Locatelli et al , in italy demoestrated the effectiveness and safety of once monthly CERA in maintating HG level in patients with chronic kidney disease on conservative measures which goes in accordance with the result of our trial on the CKD group .
(18)
Our trial result is largely supported by the recent K-DIGO (kidney disease initiatives for global outcome ) guidelines on management OF anaemia in chronic kidney disease and the position statement of EUROPEAN best practice guidelines on anemia of chronic kidney disease which both showed the importance of use of erythrocyte stimulating agents in their protocols and demonstrated the efficacy and safety of the long acting continuous erythropoietin stimulating agents (CERA) in management of anemia both in CKD and HD patients. Weak points of our trial include that it was open labeled as the investigator and patients knew the administered drug , that we did not compare the efficacy against a standard erythropoietin therapy (erythropoietin Alfa ) to compare efficacy and safety profiles and we did not study the effects of co administered standard drugs that were used concomitantly as part of anemia management protocol in our center ( iron , vitamin B , folic acid ) . CONCLUSION We can conclude that the long acting erythropoietin stimulating therapy through using CERA (CONTINOUS ERYTHROPOEITIN RECEPTOR STIMULATOR) once monthly use is effective and safe in maintaining target HB level at the recommended target by the current practice guidelines K-DIGO and European best practice guidelines and there was no recorded side effects of its use either by intravenous or subcutaneous use . 
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